FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019000543> ?p ?o ?g. }

• W2019000543 endingPage "62" @default.
• W2019000543 startingPage "56" @default.
• W2019000543 abstract "We have identified several eye muscle antigens and studied the significance of the corresponding serum autoantibodies in patients with Graves' disease. Of these antigens, only calsequestrin is expressed more in eye muscle than other skeletal muscles, which could explain at least partly the specific involvement of eye muscle in patients with Graves' disease. Earlier, we found a modest relationship between anti-calsequestrin antibodies and ophthalmopathy, but in that study we used calsequestrin prepared from rabbit heart muscle and measured antibodies by immunoblotting. We have reinvestigated the prevalences of anti-calsequestrin antibodies in larger groups of well-characterized patients with thyroid autoimmunity with and without ophthalmopathy and control patients and healthy subjects, using standard enzyme-linked immunosorbent assay incorporating highly purified rabbit skeletal muscle calsequestrin, which has a 97% homology with human calsequestrin, as antigen. Anti-calsequestrin antibodies were detected in 78% of patients with active congestive ophthalmopathy, in 92% of those with active inflammation and eye muscle involvement, but in only 22% of patients with chronic, 'burnt out' disease. Tests were also positive in 5% of patients with Graves' hyperthyroidism without evident ophthalmopathy (two patients) and one patient with 'watery eyes' but no other clear signs of congestive ophthalmopathy and IgA nephropathy and no known thyroid disease, but in no patient with Hashimoto's thyroiditis, toxic nodular goitre, non-toxic multi-nodular goitre or diabetes, or age- and sex-matched healthy subjects. In serial studies of all 11 patients with Graves' hyperthyroidism who had active ophthalmopathy at the time of the first clinic visit, or developed eye signs during the first 6 months, and positive anti-calsequestrin antibodies in at least one sample, anti-calsequestrin antibodies correlated with the onset of ocular myopathy in six patients. Antibodies targeting calsequestrin appear to be specific markers for ophthalmopathy and sensitive indicators of the ocular myopathy subtype of ophthalmopathy in patients with thyroid autoimmunity. However, these results must be considered preliminary until a large prospective study of patients with newly diagnosed Graves' hyperthyroidism, in which serum levels of calsequestrin antibodies are correlated with clinical changes and orbital eye muscle and connective tissue/fat volumes, has been carried out." @default.
• W2019000543 created "2016-06-24" @default.
• W2019000543 creator A5012702351 @default.
• W2019000543 creator A5023767557 @default.
• W2019000543 creator A5024056150 @default.
• W2019000543 creator A5029070325 @default.
• W2019000543 creator A5065427815 @default.
• W2019000543 creator A5066629521 @default.
• W2019000543 creator A5076913430 @default.
• W2019000543 date "2006-05-22" @default.
• W2019000543 modified "2023-10-15" @default.
• W2019000543 title "Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves’ disease" @default.
• W2019000543 cites W1963639559 @default.
• W2019000543 cites W1971240351 @default.
• W2019000543 cites W1974503381 @default.
• W2019000543 cites W1980611859 @default.
• W2019000543 cites W1986612162 @default.
• W2019000543 cites W1988076335 @default.
• W2019000543 cites W2002998736 @default.
• W2019000543 cites W2012067102 @default.
• W2019000543 cites W2014266401 @default.
• W2019000543 cites W2025223766 @default.
• W2019000543 cites W2035849051 @default.
• W2019000543 cites W2039932112 @default.
• W2019000543 cites W2046383243 @default.
• W2019000543 cites W2048862214 @default.
• W2019000543 cites W2052365721 @default.
• W2019000543 cites W2089992103 @default.
• W2019000543 cites W2093870471 @default.
• W2019000543 cites W2099380557 @default.
• W2019000543 cites W2106695635 @default.
• W2019000543 cites W2110096739 @default.
• W2019000543 cites W2131516732 @default.
• W2019000543 cites W2134145268 @default.
• W2019000543 cites W2139606081 @default.
• W2019000543 cites W2143604328 @default.
• W2019000543 cites W2154999896 @default.
• W2019000543 cites W2167793446 @default.
• W2019000543 cites W2170008249 @default.
• W2019000543 cites W2395748539 @default.
• W2019000543 cites W4248098588 @default.
• W2019000543 cites W4376598022 @default.
• W2019000543 doi "https://doi.org/10.1111/j.1365-2249.2006.03110.x" @default.
• W2019000543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1941994" @default.
• W2019000543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16792674" @default.
• W2019000543 hasPublicationYear "2006" @default.
• W2019000543 type Work @default.
• W2019000543 sameAs 2019000543 @default.
• W2019000543 citedByCount "44" @default.
• W2019000543 countsByYear W20190005432012 @default.
• W2019000543 countsByYear W20190005432013 @default.
• W2019000543 countsByYear W20190005432014 @default.
• W2019000543 countsByYear W20190005432015 @default.
• W2019000543 countsByYear W20190005432016 @default.
• W2019000543 countsByYear W20190005432017 @default.
• W2019000543 countsByYear W20190005432018 @default.
• W2019000543 countsByYear W20190005432019 @default.
• W2019000543 countsByYear W20190005432020 @default.
• W2019000543 countsByYear W20190005432021 @default.
• W2019000543 crossrefType "journal-article" @default.
• W2019000543 hasAuthorship W2019000543A5012702351 @default.
• W2019000543 hasAuthorship W2019000543A5023767557 @default.
• W2019000543 hasAuthorship W2019000543A5024056150 @default.
• W2019000543 hasAuthorship W2019000543A5029070325 @default.
• W2019000543 hasAuthorship W2019000543A5065427815 @default.
• W2019000543 hasAuthorship W2019000543A5066629521 @default.
• W2019000543 hasAuthorship W2019000543A5076913430 @default.
• W2019000543 hasBestOaLocation W20190005431 @default.
• W2019000543 hasConcept C113217602 @default.
• W2019000543 hasConcept C126322002 @default.
• W2019000543 hasConcept C134018914 @default.
• W2019000543 hasConcept C159654299 @default.
• W2019000543 hasConcept C163764329 @default.
• W2019000543 hasConcept C203014093 @default.
• W2019000543 hasConcept C2775953344 @default.
• W2019000543 hasConcept C2776652619 @default.
• W2019000543 hasConcept C2776685619 @default.
• W2019000543 hasConcept C2777300911 @default.
• W2019000543 hasConcept C2779134260 @default.
• W2019000543 hasConcept C2779959927 @default.
• W2019000543 hasConcept C2780130043 @default.
• W2019000543 hasConcept C519063684 @default.
• W2019000543 hasConcept C526584372 @default.
• W2019000543 hasConcept C71924100 @default.
• W2019000543 hasConcept C90924648 @default.
• W2019000543 hasConceptScore W2019000543C113217602 @default.
• W2019000543 hasConceptScore W2019000543C126322002 @default.
• W2019000543 hasConceptScore W2019000543C134018914 @default.
• W2019000543 hasConceptScore W2019000543C159654299 @default.
• W2019000543 hasConceptScore W2019000543C163764329 @default.
• W2019000543 hasConceptScore W2019000543C203014093 @default.
• W2019000543 hasConceptScore W2019000543C2775953344 @default.
• W2019000543 hasConceptScore W2019000543C2776652619 @default.
• W2019000543 hasConceptScore W2019000543C2776685619 @default.
• W2019000543 hasConceptScore W2019000543C2777300911 @default.
• W2019000543 hasConceptScore W2019000543C2779134260 @default.
• W2019000543 hasConceptScore W2019000543C2779959927 @default.
• W2019000543 hasConceptScore W2019000543C2780130043 @default.

• next